Predictive Oncology 8-K: Leadership & Compensation Changes Reported
Ticker: AGPU · Form: 8-K · Filed: Feb 8, 2024 · CIK: 1446159
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Predictive Oncology just filed an 8-K about leadership and pay changes, watch for details!**
AI Summary
Predictive Oncology Inc. reported on February 2, 2024, that it filed an 8-K regarding the departure or election of directors and officers, as well as compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should pay attention to the specifics of these changes, as new leadership or altered compensation structures can signal shifts in company priorities or financial stability, directly affecting stock performance.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's future strategy, operational efficiency, and financial performance, directly impacting shareholder value.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty, but the specific details are not yet public, making the exact impact unknown.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details on the reported leadership and compensation changes, as these will provide clarity on the potential impact to the company's strategy and financial outlook.
Key Numbers
- 001-36790 — Commission File Number (identifies the company's filings with the SEC)
- 33-1007393 — IRS Employer Identification No. (unique tax identification number for the company)
Key Players & Entities
- Predictive Oncology Inc. (company) — the registrant filing the 8-K
- February 2, 2024 (date) — date of the earliest event reported in the 8-K
- Delaware (company) — state of incorporation for Predictive Oncology Inc.
- 001-36790 (dollar_amount) — Commission File Number
- 33-1007393 (dollar_amount) — IRS Employer Identification No.
Forward-Looking Statements
- Predictive Oncology Inc. will announce specific details regarding executive changes or compensation adjustments within the next quarter. (Predictive Oncology Inc.) — medium confidence, target: 2024-05-08
FAQ
What is the primary purpose of this 8-K filing by Predictive Oncology Inc.?
The primary purpose of this 8-K filing, as indicated by 'ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', is to report changes related to the company's leadership and executive compensation.
What was the earliest event reported date in this 8-K filing?
The earliest event reported date in this 8-K filing was February 2, 2024, as stated under 'Date of Report (Date of earliest event reported): February 2, 2024'.
Where is Predictive Oncology Inc.'s principal executive office located?
Predictive Oncology Inc.'s principal executive office is located at 91 43rd Street, Suite 110, Pittsburgh, Pennsylvania 15201, according to the 'Address of Principal Executive Offices' section.
What is the telephone number for Predictive Oncology Inc.?
The telephone number for Predictive Oncology Inc. is (412) 432-1500, as listed under 'Registrant’s telephone number, including area code'.
What is Predictive Oncology Inc.'s state of incorporation?
Predictive Oncology Inc.'s state of incorporation is Delaware, as specified in the filing under 'State or Other Jurisdiction of Incorporation'.
Filing Stats: 424 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-02-08 17:00:02
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
Filing Documents
- f8k_020824.htm (8-K) — 19KB
- 0001171843-24-000689.txt ( ) — 191KB
- poai-20240202.xsd (EX-101.SCH) — 3KB
- poai-20240202_lab.xml (EX-101.LAB) — 34KB
- poai-20240202_pre.xml (EX-101.PRE) — 22KB
- f8k_020824_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2, 2024, Predictive Oncology Inc. (the "Company") and Pamela Bush, Ph.D., MBA, the Company's Chief Business Officer, agreed that Dr. Bush will leave the Company effective February 15, 2024. The Company has initiated a search to fill this function, which is consistent with its broader corporate development strategy.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY inc. Date: February 8, 2024 By: /s/ Josh Blacher Name: Josh Blacher Title: Chief Financial Officer